🔗 Share this article

An underground market for unapproved weight-loss drugs is being driven by social media fitness personalities and vendors on communication apps, based on new investigations.

Investigational Treatment Acquiring Traction Via Social Media

Retatrutide, which remains in research studies, is being advertised by social media influencers for its alleged fat-burning properties. Viewers are urged to contact these profiles directly for supplier links, while also receiving discount codes.

Active Commerce on Social Networks

Separately, a flourishing market exists on messaging services, where groups with thousands of members share “before and after” photos, injection guides and assertions of rapid British shipping. Sellers market the substance there before directing customers to other platforms for transactions.

Learning About Retatrutide

Retatrutide is an experimental injectable developed by US drugmaker Eli Lilly. The treatment affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could help individuals reduce up to 25% of their total weight. Nicknamed the “triple G”, the drug is being hailed digitally as the next Ozempic.

Healthcare Experts Express Worries

Nevertheless, doctors and chemists have warned that the sale of what remains an unapproved drug in the UK is worrisome and could result in users injecting substances of unknown origin.

Several professionals said the demand for retatrutide could be linked to the increasing cost of approved weight loss products such as Mounjaro.

Legal Status and Enforcement

Marketing retatrutide on social media or Telegram is prohibited in the UK, as it is an unlicensed drug that must not be marketed or supplied for personal consumption under the British medical regulations.

Some influencers try to circumvent the regulations by referring to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted substance, but advertising and distribution can still violate pharmaceutical, advertising, and consumer laws, potentially leading to penalties, legal action or prison.

Service Response and Content Removal

According to the social media company, the service has taken down problematic material and prohibited related hashtags and query recommendations. The organization stated it was committed to maintaining the service safe and investing in strengthening compliance measures.

Online Marketplace Activities

Research also found groups with up to 9,000 participants marketing retatrutide using the platform's built-in discovery tool, which operates like a public directory. Typing “retatrutide” instantly displays channels with numerous of members, populated with photos of weight loss, glowing reviews and step-by-step instructions for mixing or administering at home.

After minutes of entering one group, a seller posted contact information, where the majority of purchases occur. The vendor sent an instruction manual and guaranteed shipping within 48 hours. When asked whether the substance was authentic, one vendor said: “You can’t be sure.” Another provided a photo of a supposed laboratory certificate. None asked about body mass, health issues or previous experience.

Product Details and Pricing

Inside these groups, messages show black plastic parcels with postal service stickers, claiming to contain fresh supplies. One message read: “It took eight of us to load them this morning.”

Buyers can select between dry substance containers, prepared at home with purified liquid, or ready-to-use injectors typically sold at 160 pounds for 20 milligrams. When questioned how much time a pen should be used, sellers give contradictory responses varying between a few weeks to “depends on your body”.

Platform Oversight and Security Actions

A representative for Telegram stated it regularly moderated harmful material on its platform including content that promoted the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“Individuals are injecting materials they cannot confirm. Even if the research behind this drug is sound, these online versions may not include what they advertise,” said a pharmacy expert, the director of pharmacy at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor linked the increase in demand to recent cost increases for authorized slimming medications such as Mounjaro. “With costs increasing, patients are turning to social media. But counterfeit injections are extremely risky. You can’t be certain what’s inside or whether the conditions they were produced in was sterile,” she said.

Her staff has already encountered individuals harmed by self-injection from unverified sources. “We recognize the disappointment, but purchasing from messaging apps or communication platforms is taking chances with your well-being,” said the doctor. “These materials could be impure or incorrectly dosed.”

Manufacturer Statement

A spokesperson from Eli Lilly stated the substance was in phase 3 research studies and had not been reviewed or authorized by any government authority globally. “Therefore at this point no one can market [it] for human use,” they said, adding that any item “misleadingly claiming itself as a company investigational product not yet authorized … may subject patients to potentially significant health risks”.